Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

May 29, 2020 updated by: Allergan

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
594

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Chatsworth, Australia, New South Wales
        • Vision Eye Institute Chatswood
      • Fitzroy, Australia, Victoria 3065
        • Melbourne Eye Specialists
      • Glen Waverley, Australia, Vctoria 3150
        • Waverley Eye Clinic
      • Paramatta, Australia, New South Wales
        • Marsden Eye Specialists, Parramatta
      • Preston, Australia, Victoria 3072
        • Preston Eye Clinic
  • Austria
      • Graz, Austria, A-8036
        • University of Graz
      • Vienna, Austria, 1090
        • University of Vienna
  • Belgium
      • Leuven, Belgium, B-3000
        • University Hospitals Leuven
      • Liege, Belgium, 4000
        • CHU Sart Tilman
  • Brazil
      • Rio Verde, Brazil, 79002-075
        • Hospital de Olhos MS
      • Sao Paulo, Brazil, 04023-062
        • Escola Paulista de Medicina
      • Sao Paulo, Brazil, 14049-900
        • Hospital das Clínicas - Faculdade de Medicina
    • Goias
      • Goiania, Goias, Brazil, 74180-010
        • Universidade Federal de Goias
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazil, 30140-090
        • Elo Oftalmologistas Associados
    • Sao Paulo
      • Campinas, Sao Paulo, Brazil, 13010-111
        • Nova Campinas Oftalmologia
      • Osasco, Sao Paulo, Brazil, 06010-130
        • Hospital Medicina dos Olhos
  • Denmark
      • Glostrup, Denmark, 2600
        • Glostrup Hospital
  • Hong Kong
      • Hong Kong, Hong Kong
        • The University of Hong Kong
      • Hong Kong, Hong Kong
        • Hong Kong Eye Hospital
  • Hungary
      • Pecs, Hungary, H-7621
        • Ganglion Medical Center
      • Szombathely, Hungary, H-9700
        • Markusovszky Korhaz
      • Zalaegerszeg, Hungary, H-8900
        • Zala Megyei Kórház
  • Israel
      • Ashkelon, Israel, 78278
        • Barzilai Medical Center
      • Haifa, Israel, 31096
        • Rambam Medical Center
      • Haifa, Israel, 34362
        • Carmel Medical Center
      • Haifa, Israel, 31048
        • Bnai Zion M.C.
  • Peru
      • Lima, Peru, Lima 27
        • Centro Oftalmológico Mácula Diagnóstico y Tratamiento
  • Philippines
      • Makati, Philippines, 1200
        • Asian Eye Institute
      • Makati, Philippines, 1200
        • Pacific Eyecare & Laser Institute
      • Makati, Philippines, 1229
        • Makati Medical Center
  • Poland
      • Bydgoszcz, Poland, 85-631
        • Prywatna Klinika Okulistyczna OFTALMIKA
      • Gdansk, Poland, 80-211
        • Optimum Profesorskie Centrum Okulistyki
      • Lublin, Poland, 20-079
        • Public Clinical Hospital No. 1
      • Nowy Targ, Poland, 34-400
        • ZOZ OKO- TEST Poradnia Okulistyczna
      • Olsztyn, Poland, 10-424
        • Diagnostic and Microsurgery Center of the Eye LENS
      • Warsaw, Poland, 01-364
        • Retina Sp. z o.o
      • Warsaw, Poland, 01-755
        • Klinika Okulistyki WIML
      • Warszawa, Poland, 01-755
        • Uniwersytecki Szpital Kliniczny
      • Wroclaw, Poland, 50-368
        • Uniwersyteck Szpital Kliniczny
  • Spain
      • Barcelona, Spain, 08006
        • Institut Clinic d'Oftalmologia
      • Barcelona, Spain, 08017
        • Institut Catala de la Retina
      • Barcelona, Spain, 08195
        • Hospital General de Catalunya
      • Cordoba, Spain, 14004
        • Hospital Universitario Reina Sofia
      • Madrid, Spain, 28004
        • Hospital Clinico San Carlos
      • Sevilla, Spain, 41071
        • Hospital Universitario Virgen Macarena
      • Valencia, Spain, 46017
        • Hospital General
      • Valladolid, Spain, 47012
        • Hospital Universitario Rio Hortega
      • Zaragoza, Spain, 50009
        • Hospital Universitario Miguel Servet
  • Taiwan
      • Hualien, Taiwan, 970
        • Buddhist Tzu Chi General Hospital (BTCGH)
      • Kaohsiung, Taiwan, 81362
        • Kaohsiung Veterans General Hospital
  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85050
        • Arizona Glaucoma Specialists
    • California
      • Glendale, California, United States, 91205
        • Lugene Eye Institute
      • Irvine, California, United States, 92604
        • Lakeside Vision Center
      • La Jolla, California, United States, 92037
        • Hamilton Glaucoma Center, Shiley Eye Center UCSD
      • Long Beach, California, United States, 90808
        • Atlantis Eye Care
      • Los Angeles, California, United States, 90048
        • Glaucoma Institute of Beverly Hills
      • Montebello, California, United States, 90640
        • Montebello Medical Eye Center Inc.
      • Palo Alto, California, United States, 94303
        • Stanford University
      • Pasadena, California, United States, 91107
        • Foothill Eye Institute
      • Rancho Cordova, California, United States, 95670
        • Martel Eye Medical Group
      • Sacramento, California, United States, 95815
        • Grutzmacher, Lewis and Sierra, Inc.
      • San Francisco, California, United States, 94115
        • Pacific Eye Associates
    • Colorado
      • Colorado Springs, Colorado, United States, 80907
        • Eye Associates of Colorado Springs
    • Florida
      • Atlantis, Florida, United States, 33461
        • Palm Beach Eye Center, INC
      • Crystal River, Florida, United States, 34429
        • Nature Coast Clinical Research
      • Jacksonville, Florida, United States, 32204
        • Levenson Eye Associates
      • Stuart, Florida, United States, 34994
        • East Florida Eye Institute
      • Tampa, Florida, United States, 33603
        • International Research Center
    • Georgia
      • Roswell, Georgia, United States, 30076
        • Coastal Research Associates, LLC
    • Illinois
      • Chicago, Illinois, United States, 60619
        • Chicago Eye Specialists
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University School of Medicine
    • Kansas
      • Shawnee Mission, Kansas, United States, 66204
        • Heart of America Eye Care PA
    • Louisiana
      • New Orleans, Louisiana, United States, 70112
        • Tulane Medical Center
    • Maryland
      • Chevy Chase, Maryland, United States, 20815
        • Eye Doctors of Washington
    • Massachusetts
      • Quincy, Massachusetts, United States, 02169
        • MedRACS, LLC
      • Waltham, Massachusetts, United States, 02451
        • Ocular Immunology and Uveitis Foundation
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan
    • Minnesota
      • Bloomington, Minnesota, United States, 55431
        • Minnesota Eye Constultants, P.A.
    • Missouri
      • Chesterfield, Missouri, United States, 63017
        • Lifelong Vision Foundation
      • Kansas City, Missouri, United States, 64154
        • Moyes Eye Center, PC
    • New Jersey
      • South Orange, New Jersey, United States, 07079
        • Northern New Jersey Eye Institute P.A.
    • New York
      • Bethpage, New York, United States, 11714
        • Eyecare Ophthalmology Associates, PC
      • Bronx, New York, United States, 10467
        • Montefiore Medical Center
      • New York, New York, United States, 10003
        • New York Eye and Ear Infirmary of Mount Sinai
      • Rochester, New York, United States, 14618
        • Rochester Ophthalmological Group PC
      • Rockville Centre, New York, United States, 11570
        • 2000 North Village Avenue
      • Slingerlands, New York, United States, 12159
        • Glaucoma Consultants of the Capital Region
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • 8 Medical Park Drive
      • Elizabeth City, North Carolina, United States, 27909
        • Albemarle Clinical Trials, LLC
    • Ohio
      • Cleveland, Ohio, United States, 44106
        • University Hospitals of Cleveland
      • Columbus, Ohio, United States, 43212
        • The Ohio State University Havener Eye Institute
    • Oregon
      • Eugene, Oregon, United States, 97401
        • Drs Fine Hoffman & Sims, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Wills Eye Institute - Glaucoma Research Center
      • Pittsburgh, Pennsylvania, United States, 15219
        • Associates in Ophthalmology
    • South Carolina
      • Florence, South Carolina, United States, 29501
        • Carolinas Centers for Sight PC
    • Tennessee
      • Memphis, Tennessee, United States, 38120
        • VRF Eye Specialty Group
      • Nashville, Tennessee, United States, 37205
        • Nashville Vision Associates
    • Texas
      • Austin, Texas, United States, 78731
        • Keystone Research, LTD
      • Dallas, Texas, United States, 75231
        • Glaucoma Associates of Texas
      • El Paso, Texas, United States, 79902
        • The Cataract, Glaucoma & Refractive Surgery Center
      • Houston, Texas, United States, 77025
        • Houston Eye Associates
      • San Antonio, Texas, United States, 78229
        • Focal Point Vision
      • San Antonio, Texas, United States, 78240
        • Medical Center Ophthalmology Associates
      • San Antonio, Texas, United States, 78234
        • R and R Eye Research, LLC
    • Virginia
      • Lynchburg, Virginia, United States, 24502
        • Piedmont Eye Center
    • West Virginia
      • Morgantown, West Virginia, United States, 26506
        • West Virginia University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

-Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.

Exclusion Criteria:

  • Previous enrollment in another Allergan Bimatoprost SR Study.
  • Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
  • Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration
  • History of glaucoma surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Bimatoprost SR 15 μg
Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Drug: Bimatoprost SR
Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
Other Names:
  • AGN-192024
Drug: Active Comparator: Timolol 0.5%
Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Other: Sham: Applicator Without Needle
Sham administered on Day 1, Week 16, and Week 32.
Drug: Timolol Vehicle (placebo)
Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
Experimental: Bimatoprost SR 10 μg
Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Drug: Bimatoprost SR
Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
Other Names:
  • AGN-192024
Drug: Active Comparator: Timolol 0.5%
Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Other: Sham: Applicator Without Needle
Sham administered on Day 1, Week 16, and Week 32.
Drug: Timolol Vehicle (placebo)
Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
Active Comparator: Timolol 0.5%
Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Drug: Active Comparator: Timolol 0.5%
Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
Other: Sham: Applicator Without Needle
Sham administered on Day 1, Week 16, and Week 32.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2)
Time Frame: Baseline (Hours 0 and 2) to Week 12 (Hours 0 and 2)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. A mixed-effects model with repeated measures (MMRM) was used for analyses. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Baseline (Hours 0 and 2) to Week 12 (Hours 0 and 2)
IOP in the Study Eye at Week 2 (Hour 0)
Time Frame: Week 2 (Hour 0)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses.
Week 2 (Hour 0)
IOP in the Study Eye at Week 2 (Hour 2)
Time Frame: Week 2 (Hour 2)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses.
Week 2 (Hour 2)
IOP in the Study Eye at Week 6 (Hour 0)
Time Frame: Week 6 (Hour 0)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses.
Week 6 (Hour 0)
IOP in the Study Eye at Week 6 (Hour 2)
Time Frame: Week 6 (Hour 2)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses.
Week 6 (Hour 2)
IOP in the Study Eye at Week 12 (Hour 0)
Time Frame: Week 12 (Hour 0)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses.
Week 12 (Hour 0)
IOP in the Study Eye at Week 12 (Hour 2)
Time Frame: Week 12 (Hour 2)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses.
Week 12 (Hour 2)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change From Baseline in IOP in the Study Eye
Time Frame: Baseline (Hours 0 and 2) to Weeks 2 and 6 (Hours 0 and 2)
IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening.
Baseline (Hours 0 and 2) to Weeks 2 and 6 (Hours 0 and 2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Allergan

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Marina Bejanian, Allergan

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 15, 2014

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 19, 2018

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 19, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 22, 2014

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 22, 2014

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 25, 2014

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 11, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 29, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 192024-091
  • 2014-003037-26 (EudraCT Number)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ocular Hypertension

Clinical Trials on Bimatoprost SR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings